Welcome and Opening Remarks

Welcome8:00am - 8:15amTed W. Love, M.D.
Chief Executive Officer, Global Blood Therapeutics, Inc.
NHLBI and SCD8:15am - 8:45amW. Keith Hoots, M.D.
Director of the Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute (NHLBI)


Panel 1: Beyond VOC – Clinical Consequences of SCD

Moderator8:45am - 9:45amKen Bridges, M.D.
Vice President of Medical Affairs, Global Blood Therapeutics
PresentationAnemia and Clinical Sequelae in SCD:
Victor R. Gordeuk, M.D.
Professor of Medicine, Hematology/Oncology, University of Illinois at Chicago
PresentationNeurocognitive Impact of SCD:
Carlton Dampier, M.D.
Professor Division of Hematology/Oncology - Oncology Department of Pediatrics, Aflac Cancer and Blood Disorders Center
PresentationChronic Organ Failure in SCD:
Elliott Vichinsky, M.D.
Medical Director, Hematology/Oncology, UCSF Benioff Children's Hospital Oakland


Break (9:45am – 10:00am)


Panel 2: Impact of SCD on Quality of Life

Moderator10:00am - 10:45amLanetta Bronte, M.D., M.P.H., MSPH
President & Chief Executive Officer, Foundation for Sickle Cell Disease Research, Sickle Cell Care and Research Network
PanelistsDr. Lakiea Bailey, Ph.D.
Director, Sickle Cell Community Consortium

Charlotte Flemmings, B.A., M.P.A.
Founder, Sickle Cycle

Dominique Goodson, B.A.
Project Manager at Sickle Cell Disease Community Forum

Dr. Terry Jackson, Ph.D.
Patient Advocate

Dr. Carolyn Rowley, Ph.D.
Founder & Executive Director, Cayenne Wellness Center

Cassandra Trimnell, B.A.
Founder & Executive Director, Sickle Cell 101


Panel 3: Innovative Care Delivery – HRSA SCD Treatment Demonstration Project

Moderator10:45am - 11:45am
PresentationDiane Nugent, M.D.
Chief Hematology, Children’s Hospital Orange County

Lisa M. Shook, M.A., MCHES, CCP
Assistant Professor of Pediatrics, Cincinnati Children’s

Rosalyn Stewart, M.D., MBA, MS
Associate Professor of Medicine, Johns Hopkins Medicine

John J. Strouse, M.D., Ph.D.
Associate Professor of Medicine, Duke University Medical Center


Panel 4: SCDAA Update

Presentation11:45am - 12:15pmBeverley Francis-Gibson, B.A., M.A.
President & Chief Executive Officer, Sickle Cell Disease Association of America, Inc.


Lunch (12:15pm – 1:00pm)


Panel 5: What is Fueling the Increased Biopharma Attention on SCD? – Research Analyst Panel

Moderator1:05pm - 1:35pmMyesha Lacy
Vice President of Investor Relations and Corporate Communications, Global Blood Therapeutics
PanelistsMark Breidenbach, Ph.D.
Executive Director and Senior Analyst, Oppenheimer & Co.

Raju Prasad, Ph.D.
Analyst, William Blair


Company Presentations

Global Blood Therapeutics (GBT)1:35pm - 2:00pmTed W. Love, M.D.
Chief Executive Officer
addmedica2:00pm - 2:25pmBernard Dauvergne, PharmD
Executive Director
CRISPR Therapeutics2:25pm - 2:50pmKrista McKerracher
Head, Hemoglobinopathy Programs
Emmaus Life Sciences2:50pm - 3:15pmDarrell W. Harrington, M.D., MACP
Chief Medical Officer
Break (3:15pm - 3:30pm)
Imara3:30pm - 3:55pmRahul Ballal, Ph.D.
Chief Executive Officer
Ironwood Pharmaceuticals3:55pm - 4:20pmMark Currie, Ph.D.
Senior Vice President, Chief Scientific Officer, and President of R&D
Modus Therapeutics4:20pm - 4:45pmEllen Donnelly, Ph.D.
Chief Executive Officer



Closing4:45pm - 4:50pmTed W. Love, M.D.
Chief Executive Officer, Global Blood Therapeutics, Inc.


Reception (5:00pm – 6:30pm)